NCT05565092 (PHOENIX) is a Phase 2 clinical trial of ALXN1820 in Sickle Cell Disease (SCD), sponsored by Alexion Pharmaceuticals, Inc..

Who is sponsoring NCT05565092?

NCT05565092 is sponsored by Alexion Pharmaceuticals, Inc..

What drugs are being tested in NCT05565092?

Interventions in NCT05565092: ALXN1820.

What condition does NCT05565092 study?

NCT05565092 studies Sickle Cell Disease (SCD).

Is NCT05565092 still recruiting?

NCT05565092 is currently terminated. Last updated 13 January 2025.

Are results published for NCT05565092?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-01-13 · How we verify

NCT05565092: PHOENIX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease

Terminated Phase 2 Results posted Last updated 13 January 2025

What this trial tests

Phase 2 trial testing ALXN1820 in Sickle Cell Disease (SCD) in 2 participants. Terminated before completion.

Timeline

22 February 2023

Primary endpoint
9 January 2024

9 January 2024

Quick facts

Lead sponsor	Alexion Pharmaceuticals, Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	22 February 2023
Primary completion	9 January 2024
Estimated completion	9 January 2024
Sites	2 locations across United States

Drugs / interventions tested

ALXN1820 — full drug profile →

Conditions studied

Sickle Cell Disease (SCD) — all drugs for Sickle Cell Disease (SCD) →

Sponsor

Alexion Pharmaceuticals, Inc. — full company profile →

Who can join

18 and older, any sex, with Sickle Cell Disease (SCD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to assess the safety and tolerability of ALXN1820 SC (subcutaneous) in participants with SCD (Sickle Cell Disease).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current and Future Therapeutics for Treating Patients with Sickle Cell Disease.
Barak M, Hu C, Matthews A, Fortenberry YM. · · 2024 · cited 14× · PMID 38786070 · DOI 10.3390/cells13100848
Using disease-modifying therapies in sickle cell disease.
Rai P, Ataga KI. · · 2023 · cited 4× · PMID 38066905 · DOI 10.1182/hematology.2023000485

Verify or expand the search:

Other recruiting trials for Sickle Cell Disease (SCD)

Currently open trials in the same condition.

NCT06619197 — Exploratory Study on Global Reflexology in Sickle Cell Disease · NA · recruiting
NCT06887907 — Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient · recruiting
NCT06941389 — Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therap · recruiting
NCT03814746 — Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients · Phase 3 · active not recruiting

Other Alexion Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT06015750 — Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia · Phase 4 · withdrawn
NCT07352423 — Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants · Phase 1 · recruiting
NCT07221838 — A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab · Phase 4 · recruiting
NCT07413250 — Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis o · active not recruiting
NCT07308574 — Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05565092 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alexion Pharmaceuticals, Inc.
Last refreshed: 13 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05565092.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing